UNIVERSITE DE MONTPELLIER;INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM);INSTITUT REGIONAL DU CANCER DE MONTPELLIER (ICM)
发明人:
GONGORA, CELINE,TOSI, DIEGO
申请号：
CA3084474
公开号：
CA3084474A1
申请日:
2018.11.14
申请国别(地区):
CA
年份:
2019
代理人:
摘要：
The invention concerns a pharmaceutical combination of an inhibitor of the androgen receptor signaling pathway and of a p38 inhibitor for use in the treatment of prostate cancer in individuals wherein the prostate tumor cells express the AR-V7 variant androgen receptor protein or for preventing the occurrence of resistance in patients suffering from prostate cancer treated by an inhibitor of the androgen receptor signaling pathway. The invention further concerns a pharmaceutical composition comprising enzalutamide, abiraterone or apalutamide and a p38 inhibitor selected from LY2228820 and ARRY-614, and at least one pharmaceutically acceptable excipient. The invention also concerns the use of a p38 inhibitor for restoring the sensitivity to androgen-deprivation therapy (ADT) in patients suffering from prostate cancers having acquired a resistance to ADT following a treatment with an inhibitor of the androgen receptor signaling pathway and wherein the prostate tumour cells express the AR-V7 variant androgen receptor protein.
